IP Library › Granted Patent US 11,229,705
Granted Patent B2
US 11,229,705 · App. 16/472,216 · Granted Jan 25, 2022

Coated nanoparticles for use for modulating electrical polarization of neurons

Inventors: Agnès Pottier (Paris, FR); Laurent Levy (Paris, FR); Marie-Edith Meyre (Saint Mande, FR)
Assignee: NANOBIOTIX
A61K41/0052A61K41/0028A61P25/28A61N1/0456A61N1/36025A61N2/006A61P25/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,229,705
App. No.
16/472,216
Granted
Jan 25, 2022
Kind
B2
Abstract

The present invention relates to the medical field, in particular to the modulation of electrical polarization of neurons. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use for modulating electrical polarization of neurons in a subject, for example for use in prevention or treatment of a neuronal disease in a subject, typically by modulating electrical polarization of neurons in the subject, wherein i) when the nanoparticle or nanoparticles' aggregate is exposed to a light source, the nanoparticle's or nanoparticles' aggregate's material is selected from a material enabling opto-electric transduction, opto-thermal transduction or opto-optical transduction, ii) when the nanoparticle or nanoparticles' aggregate is exposed to a magnetic field, the nanoparticle's or nanoparticles' aggregate's material is selected from a material enabling magneto-electric transduction or magneto-thermal transduction, iii) when the nanoparticle or nanoparticles' aggregate's surface is exposed to an ultrasound source, the nanoparticle's or nanoparticles' aggregate's material is a material enabling acousto-electric transduction, and wherein the nanoparticle or nanoparticles' aggregate is either neutrally charged in the absence of any coating or is coated with a hydrophilic agent conferring a neutral surface charge to the nanoparticle or nanoparticles' aggregate. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.

Claims (13)

1. A method for treating a neuronal disease in a subject by modulating electrical polarization of neurons in the subject, wherein the method comprises a) administering a composition of nanoparticle or nanoparticle aggregate to the subject, wherein i) when the nanoparticle or nanoparticle aggregate is exposed to a light source, the nanoparticle or nanoparticle aggregate material is selected from a material enabling opto-electric transduction, opto-thermal transduction or opto-optical transduction, or ii) when the nanoparticle or nanoparticle aggregate is exposed to a magnetic field, the nanoparticle or nanoparticle aggregate material is a material enabling magneto-electric transduction or magneto-thermal transduction, or iii) when the nanoparticle or nanoparticle aggregate is exposed to an ultrasound source, the nanoparticle or nanoparticle aggregate material is a material enabling acousto-electric transduction, and wherein the nanoparticle or nanoparticle aggregate surface is either neutrally charged in the absence of any coating or coated with a hydrophilic agent conferring a neutral surface charge to the nanoparticle or nanoparticle aggregate, the neutral charge being of about −10 mV to +10 mV, and b) exposing the subject to a light source, a magnetic field, or an ultrasound source, thereby modulating electrical polarization of neurons in the subject, and wherein the nanoparticle or nanoparticle aggregate of step a) is at least two distinct nanoparticles and/or nanoparticle aggregates, each nanoparticle or nanoparticle aggregate consisting of a distinct material selected from a material enabling opto-electric transduction, opto-thermal transduction, opto-optical transduction, magneto-electric transduction, magneto-thermal transduction or acousto-electric transduction, and the nanoparticle or nanoparticle aggregate surface being optionally coated with a hydrophilic agent conferring a neutral surface charge to the nanoparticle or nanoparticle aggregate.

2. The method according to claim 1 , wherein the material enabling opto-electric transduction is a semiconductor material with a band gap Eg below 3.0 eV.

3. The method according to claim 1 , wherein the material enabling opto-thermal transduction is a plasmonic metal material.

4. The method according to claim 1 , wherein the material enabling opto-optical transduction is a lanthanide element-doped material selected from a lanthanide-doped oxide, a lanthanide-doped mixed-oxide, a lanthanide-doped metal-phosphate, and a lanthanide-doped metal-vanadate.

5. The method according to claim 1 , wherein the material enabling magneto-thermal transduction is a superparamagnetic material.

6. The method according to claim 1 , wherein the material enabling acousto-electric transduction is a piezoelectric material.

7. The method according to claim 1 , wherein the hydrophilic agent conferring a neutral surface charge to the nanoparticle or nanoparticle aggregate displays a functional group selected from an alcohol (R—OH), an aldehyde (R—COH), a ketone (R—CO—R), an ester (R—COOR), an acid (R—COOH), a thiol (R—SH), a saccharide, an anhydride (RCOOOC—R), and a pyrrole.

8. The method according to claim 1 , wherein the hydrophilic agent is selected from a poly(lactic acid), a polyhydroxyalkanoic acid, a polyether, a polyethylene oxide, a polyethylene glycol, a polyvinylalcohol, a polycaprolactone, a polyvinylpyrrolidone, a polysaccharide, a polypyrrole, a cyclodextrin, a thioglucose, a 2-mercaptoethanol, a 1-thioglycerol, a thiodiglycol, a hydroxybutyric acid, a hydroxymethyltriethoxysilane, a fructose 6-phosphate and a glucose 6-phosphate.

9. The method according to claim 1 , wherein the subject is a human being.

10. A method for treating a neuronal disease in a subject by modulating electrical polarization of neurons in the subject, wherein the method comprises a) administering a composition to the subject, the composition comprising nanoparticles and/or nanoparticle aggregates and a pharmaceutically acceptable support, wherein i) when the nanoparticle or nanoparticle aggregate is exposed to a light source, the nanoparticle or nanoparticle aggregate material is selected from a material enabling opto-electric transduction, opto-thermal transduction or opto-optical transduction, or ii) when the nanoparticle or nanoparticle aggregate is exposed to a magnetic field, the nanoparticle or nanoparticle aggregate material is a material enabling magneto-electric transduction or magneto-thermal transduction, or iii) when the nanoparticle or nanoparticle aggregate is exposed to an ultrasound source, the nanoparticle or nanoparticle aggregate material is a material enabling acousto-electric transduction, and wherein the nanoparticle or nanoparticle aggregate surface is either neutrally charged in the absence of any coating or coated with a hydrophilic agent conferring a neutral surface charge to the nanoparticle or nanoparticle aggregate, the neutral charge being of about −10 mV to +10 mV, and b) exposing the subject to a light source, a magnetic field, or an ultrasound source, thereby modulating electrical polarization of neurons in the subject, and

wherein the composition comprises at least two distinct nanoparticles and/or nanoparticle aggregates, each nanoparticle or nanoparticle aggregate consisting of a distinct material selected from a material enabling opto-electric transduction, opto-thermal transduction, opto-optical transduction, magneto-electric transduction, magneto-thermal transduction or acousto-electric transduction, and the nanoparticle or nanoparticle aggregate surface being optionally coated with a hydrophilic agent conferring a neutral surface charge to the nanoparticle or nanoparticle aggregate.

11. The method according to claim 10 , wherein the subject is a human being.

12. The method according to claim 1 , wherein the material enabling magneto-electric transduction is CoFe 2 O 4 @BaTiO 3 .

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED ON REEL 049729 FRAME 0403. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ENTIRE INTEREST. Recorded Jan 21, 2022
From: POTTIER, AGNES; LEVY, LAURENT; MEYRE, MARIE-EDITH
To: NANOBIOTIX S.A.
Reel/Frame 058801/0884 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2019
From: POTTIER, AGNES; LEVY, LAURENT; MEYRE, MARIE-EDITH
To: NANOBIOTIX
Reel/Frame 049729/0403 →
Priority Claims (1)
EP 16306753 · Dec 21, 2016 · regional
Continuity (1)
Related Publication 20190351057A1 · Nov 21, 2019
Cited By (1)
US 12,653,890